ClinicalTrials.gg
RecruitingNCT05890716WILLEMUpdated Nov 6, 2026

AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM)

An observational study in Cardiomyopathies, Cardiac Arrest and Cardiac Arrhythmias, sponsored by Idoven 1903 S.L.. Recruiting at 13 sites in 2 countries. Open to participants aged 4 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Idoven 1903 S.L. · Observational

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 7 months later.
Updated Nov 6, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
5,342
Ages
4 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Cardiomyopathies with a site in Spain — 13 open to participants now, 16 under way, 5 of them phase 3. Cardiomyopathies · Spain.

Planned enrollment
2nd of 16
5,342 · median 325
Started
2023
with 4 others
Observational
16 of 32
7 open now
Primary completion
2026-12
later than 1 of 15 live
Registered
18th of 32
by date

Among the 32 studies in Cardiomyopathies with a site in Spain, this one is the 2nd largest by planned enrollment of the 16 observational ones that give a count, is one of 5 that started in 2023, is one of 16 observational ones, reaches primary completion later than 1 of the 15 other live ones, and was the 18th registered.

Cardiomyopathies

556 studies on the registry are indexed under Cardiomyopathies; 153 are open to participants now.

Browse Cardiomyopathies studies →

Open to participants now

13 of the 32 studies in Cardiomyopathies with a site in Spain are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 116 Cardiomyopathies studies recruiting now, 70 (60%) set no upper age limit and 18 (16%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.

This study: 4 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Cardiomyopathies with a site in Spain, or all of them as a file.
02

Study summary

WILLEM is a multi-center, prospective and retrospective cohort study.

The study will assess the performance of a cloud-based and AI-powered ECG analysis platform, named Willem™, developed to detect arrhythmias and other abnormal cardiac patterns. The main questions it aims to answer are:

  1. A new AI-powered ECG analysis platform can automatice the classification and prediction of cardiac arrhythmic episodes at a cardiologist level.
  2. This AI-powered ECG analysis can delay or even avoid harmful therapies and severe cardiac adverse events such as sudden death.

The prerequisites for inclusion of patients will be the availability of at least one ECG record in raw data, along with patient clinical data and evolution data after more than 1-year follow-up.

Cardiac electrical signals from multiple medical devices will be collected by cardiology experts after obtaining the informed consent. Every cardiac electrical signal from every subject will be reviewed by a board-certified cardiologist to label the arrhythmias and patterns recorded in those tracings. In order to obtain tracings of relevant information, >95% of the subjects enrolled will have rhythm disorders or abnormal ECG's patterns at the time of enrollment.

Read the detailed description

The WILLEM study is an investigator-initiated, multicenter, observational trial aiming to validate a cloud-based AI-powered ECG analysis platform to early diagnose and predict the behavior of cardiac abnormalities and cardiac diseases from patients admitted to cardiovascular units. Model-derived diagnosis will be compared with cardiology expert's diagnosis in a test dataset. Clinical outcomes will be included to assess model prediction capabilities: sensitivity, specificity and accuracy. In this observational study, patients will be randomly divided into two groups: (1) a training group to design new methodologies and algorithms; and (2) a test group to evaluate performance of methodologies aiming to avoid overfitting.

Willem™ AI-powered ECG analysis platform supports the analysis of cardiac electrical signals ≥ 10 seconds onwards obtained from devices in-clinic (E.g., 12-lead ECG devices at hospitals or primary care, telemetries, monitors) and at-home or telemedicine interfaces (E.g., Holter devices, event recorders, 6, 3, 2, 1-lead ECG wearables, textile electrodes and patches for mobile cardiac telemetry).

03

Conditions studied

  • Cardiomyopathies
  • Cardiac Arrest
  • Cardiac Arrhythmias
  • Sudden Cardiac Death

Keywords

  • Artificial intelligence
  • Cardiac arrhythmias
  • Heart disease
  • Cardiac electrical signals
  • Electrocardiogram
  • Electrogram
04

Who can participate

Ages eligible
4 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients recorded with a mid to long-term ECG device according to guidelines. ECG data (ECG must have been recorded according to the technical standards for the safety and essential performance of medical electrical equipment defined in EN 60601-2-47:2015.): 12-lead ECGs including rest electrocardiograms, stress ECG Test (exercise Electrocardiogram or treadmill test), Holter devices, long-duration Holter devices, event recorders, insertable cardiac monitors, 6,3,2,1-lead ECG wearables, textile electrodes and patches, smartwatches, cardiac monitors, cardiac telemetries, hemodynamic and electrophysiology recording system (i.e., polygraphs), automatic external defibrillator (AED), semi-automatic defibrillator (DESA), home telemonitoring systems and other similar devices.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient presenting relevant cardiac arrhythmias and cardiac patterns (including supraventricular tachycardias, abnormal patterns, ventricular tachycardias, ventricular fibrillation, pulseless electrical activity or asystole among others) that have been recorded with at least one short-term ECG medical device according to guidelines with ≥1 signal-channel.
  • Patient with suspected or diagnosed acute/chronic cardiac diseases (including patients with heart failure, patients with history of cardiac arrhythmias, patients with probable coronary artery diseases, patients with cardiomyopathies, patients with pacemakers or implantable cardioverter-defibrillators (ICD), patients with indication of pacemaker or ICD in current or short-term phase, patients participating in other interventional clinical investigation, patients with hemodynamic instability or acute coronary syndromes, pregnant patients, patients with cancer and chemotherapy, patients with life-expectancy lower than 24 months, patients with in or out-of-hospital cardiac arrest with ventricular fibrillation as first documented rhythm).
  • At least one ECG tracing that can be exported in raw data.
  • Signed . Patients unable to consent, it will be requested to an authorized relative.

Exclusion criteria

Exclusion Criteria:

  • Unwillingness or inability to sign study written .
  • Unavailable or suboptimal quality of the electrocardiographic signal in raw data.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
5,342 participants (estimated)
Patient registry
No

Groups and cohorts

  • Train group

    Consecutive patients admitted to the hospital due to cardiac disorders (retrospective and prospective) with at least one relevant ECG record \>10 sec in raw data will be used to design new methodologies and algorithms for cardiac patterns recognition.

    Diagnostic Test: AI-powered ECG analysis to detect cardiac arrhythmic episodes

  • Test group

    Consecutive patients admitted to the hospital due to cardiac disorders (retrospective and prospective) with at least one relevant ECG record \>10 sec in raw data will be used to evaluate performance of methodologies aiming to avoid overfitting. Every 10 patients included in Train group; a new patient is included in the test group.

    Diagnostic Test: AI-powered ECG analysis to detect cardiac arrhythmic episodes

Interventions

  • Diagnostic testAI-powered ECG analysis to detect cardiac arrhythmic episodes

    ECG recording and processing by AI platform

06

What researchers measure

Primary outcomes

  1. Detection of cardiac arrhythmias and cardiac patterns in the electrocardiographic signals

    Willem™ heart rhythm and cardiac pattern performance compared to standard manually performed cardiologist diagnosis.

    Time frame: real time to 7 minutes

Secondary outcomes

  1. Survival at follow-up

    Patients alive at the time of follow-up

    Time frame: 1 year after the first ECG (prospective patients) or after patient enrollment (retrospective patients)

  2. Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)

    MACCE rates defined as cardiovascular and cerebrovascular events during the follow up

    Time frame: 1 year after the first ECG (prospective patients) or after patient enrollment (retrospective patients)

  3. Re-hospitalization

    Number of Re-hospitalizations during the follow up.

    Time frame: 1 year after the first ECG (prospective patients) or after patient enrollment (retrospective patients)

  4. Change in quality of life

    European Quality of Life-5 Dimensions (EQ-5D) index an utility scores anchored at 0 for death and 1 for perfect health.

    Time frame: 1 year after the first ECG (prospective patients) or after patient enrollment (retrospective patients)

07

Study locations

2 of 13 sites recruiting
  • University Medical Center Groningen
    Groningen, Provincie Groningen 9713 GZ, Netherlands
    Completed

    Not enrolling at this site.

  • Hospital Sant Joan de Déu
    Barcelona, Barcelona 08950, Spain
    Completed

    Not enrolling at this site.

  • Hospital General Universitario de Ciudad Real
    Ciudad Real, Ciudad Real 13005, Spain
    Completed

    Not enrolling at this site.

  • Complejo Hospitalario Universitario A Coruña
    A Coruña, La Coruña 15006, Spain
    Completed

    Not enrolling at this site.

  • Hospital Clínico San Carlos
    Madrid, Madrid 28040, Spain
    Completed

    Not enrolling at this site.

  • Hospital Universitario Puerta de Hierro
    Madrid, Madrid 28222, Spain
    Completed

    Not enrolling at this site.

  • Hospital Universitario General de Villalba
    Madrid, Madrid 28400, Spain
    Completed

    Not enrolling at this site.

  • Hospital Universitario del Henares
    Madrid, Madrid 28822, Spain
    Completed

    Not enrolling at this site.

  • Hospital Virgen de Arrixaca
    Murcia, Murcia 30120, Spain
    Completed

    Not enrolling at this site.

  • Clínica Universitaria Navarra
    Pamplona, Navarre 31008, Spain
    Recruiting
    • Manuel García de Yébenes Castro, MD · Contact
    • Manuel García de Yébenes Castro · Principal investigator
  • Hospital Universitario Nuestra Señora de Candelaria
    Santa Cruz de Tenerife, Santa Cruz de Tenerife 38010, Spain
    Completed

    Not enrolling at this site.

  • Hospital Universitario y Politécnico La Fe
    Valencia, Valencia 46026, Spain
    Completed

    Not enrolling at this site.

  • Hospital Universitario de Basurto
    Bilbao, Vizcaya 48013, Spain
    Recruiting
    • Alain García Olea, MD · Contact
    • Alain García Olea · Principal investigator
08

References and documents

Publications

  • Lillo-Castellano JM, Marina-Breysse M, Gomez-Gallanti A, Martinez-Ferrer JB, Alzueta J, Perez-Alvarez L, Alberola A, Fernandez-Lozano I, Rodriguez A, Porro R, Anguera I, Fontenla A, Gonzalez-Ferrer JJ, Canadas-Godoy V, Perez-Castellano N, Garofalo D, Salvador-Montanes O, Calvo CJ, Quintanilla JG, Peinado R, Mora-Jimenez I, Perez-Villacastin J, Rojo-Alvarez JL, Filgueiras-Rama D. Safety threshold of R-wave amplitudes in patients with implantable cardioverter defibrillator. Heart. 2016 Oct 15;102(20):1662-70. doi: 10.1136/heartjnl-2016-309295. Epub 2016 Jun 13. PubMed 27296239 ↗
  • Lillo-Castellano JM, Gonzalez-Ferrer JJ, Marina-Breysse M, Martinez-Ferrer JB, Perez-Alvarez L, Alzueta J, Martinez JG, Rodriguez A, Rodriguez-Perez JC, Anguera I, Vinolas X, Garcia-Alberola A, Quintanilla JG, Alfonso-Almazan JM, Garcia J, Borrego L, Canadas-Godoy V, Perez-Castellano N, Perez-Villacastin J, Jimenez-Diaz J, Jalife J, Filgueiras-Rama D. Personalized monitoring of electrical remodelling during atrial fibrillation progression via remote transmissions from implantable devices. Europace. 2020 May 1;22(5):704-715. doi: 10.1093/europace/euz331. PubMed 31840163 ↗
  • Quartieri F, Marina-Breysse M, Pollastrelli A, Paini I, Lizcano C, Lillo-Castellano JM, Grammatico A. Artificial intelligence augments detection accuracy of cardiac insertable cardiac monitors: Results from a pilot prospective observational study. Cardiovasc Digit Health J. 2022 Aug 4;3(5):201-211. doi: 10.1016/j.cvdhj.2022.07.071. eCollection 2022 Oct. PubMed 36310681 ↗
  • Martinez-Selles M, Marina-Breysse M. Current and Future Use of Artificial Intelligence in Electrocardiography. J Cardiovasc Dev Dis. 2023 Apr 17;10(4):175. doi: 10.3390/jcdd10040175. PubMed 37103054 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Apr 2023 (actual). Primary completion is estimated for Dec 2026, 44 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Nov 2026 → Dec 2026 and completion Nov 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2023
First posted
Jun 6, 2023
StartActual
Apr 4, 2023
Primary completionEst.
Dec 2026was Nov 2026
CompletionEst.
Dec 2026was Nov 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 2026→Dec 2026
Nov 6, 2026
Study completion
Nov 2026→Dec 2026
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Primary completion Nov 2026→Dec 2026
    Study completion Nov 2026→Dec 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05890716
Lead sponsor
Idoven 1903 S.L.
Collaborators
Fundación de Investigación en Red en Enfermedades Cardiovasculares, Spanish Society of Cardiology
Responsible party
Sponsor
First posted
Jun 6, 2023
Start date
Apr 4, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 6, 2026

Study contacts

Manuel Marina-Breysse, MSc, MD
Contact
manuel.marina@idoven.ai
+34618103160
José María Lillo, PhD
Contact
c@idoven.ai
María De La Parte, MD
principal investigator · Idoven 1903 S.L.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion